Machine Learning Predicts Subjective Cognitive Decline During Menopause: Novel Framework for Early Detection
July 11, 2025

Key predictors of the severity of self-reported cognitive complaints among nurses going through menopause included symptom severity and climacteric stage.

Elinzanetant Gets UK Nod for Moderate to Severe Vasomotor Symptoms in Menopause: Is the US Far Behind?
July 11, 2025

Bayer's elinzanetant gains UK approval as the first dual-action, nonhormonal treatment for menopausal symptoms.

It Takes a Multispecialty Team to Support and Sustain Patient-Centered Lifestyle Behavior Change
July 11, 2025

Lifestyle medicine integrates a spectrum of therapeutic lifestyle interventions best delivered by specialists who are often available to create a "virtual" team.

9 Drugs Approved for Primary Care: Q2 2025
July 11, 2025

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD
July 11, 2025

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

Tralokinumab Update: Positive 16-Week Interim Results Reported for ADHAND Trial in Adults with Hand Eczema
July 11, 2025

Tralokinumab met key trial endpoints with no new safety signals in treatment of moderate-to-severe hand eczema, in adults who are candidates for systemic therapy.

Obesity and Chronic Pain: Monu Khanna, MD, on Breaking the Vicious Cycle
July 10, 2025

Dr Khanna breaks down the bidirectional relationship and explains why standard pain management often falls short for people with obesity.

Real-World Data Highlight Impact of Treatment Discontinuation on Obesity Pharmacotherapy Outcomes
July 10, 2025

A recent study highlights the importance of medication adherence for significant weight loss and improved glycemic control in obesity treatment with GLP-1 agonists.

Adult Vaccines in the US: More Shots, New Dynamics on the Horizon
July 10, 2025

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years
July 10, 2025

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.